Interface Biologics Appoints Art Rosenthal to Chairman of its Board of Directors

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products recently announced the appointment of Arthur L. Rosenthal to Chairman of its Board of Directors.

Dr. Rosenthal is currently CEO of Cappella, Inc., a medical device company focused on coronary artery disease. He has previously served as Chairman and CEO of Labcoat Ltd. (Galway, Ireland), Senior VP and Chief Scientific Officer of Boston Scientific Corporation, VP of R&D for J&J Medical and VP R&D at CR Bard.

Dr. Rosenthal originally joined Interface Biologics Board in March, 2010. “We are delighted to have Art accept the position of Chairman of our Board of Directors”, stated Tom Reeves, Interface Biologics’ President & CEO. “The combination of his deep scientific knowledge and wealth of industry experience in both early stage and large multinational medical device companies is a tremendous asset to IBI. As we transition from materials research and development stage to product development and commercialization, his insights and direction will be invaluable. I look forward to his leadership as our new Chairman.”

Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. IBI’s primary technology focus areas are anti-thrombogenic devices that reduce thrombosis without the need for heparin, anti-infective polymers, and programmable combination drug delivery devices.

The comments are closed.